Organon continues to engage in support of women’s health
December 7, 2021 10:30 am EDT
Organon now the only healthcare company to have dual membership of MA and GBMA
Just five months after our launch in June 2021, Organon has become members of both Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA), and is the only healthcare company in Australia to be members of both industry representative organisations.
“Organon Australia is proud to be members of both Medicines Australia as well as Generic and Biosimilar Medicines Association. Our commitment is to the health and wellbeing of women, and we look forward to using our voice to advocate for access and innovative treatments to support a healthier every day for every woman,” said Luke Cornish, Access and External Affairs director.
“This is a very important time for the pharmaceutical industry, with Australians recognising the value that medicines and our industry brings. Our clear and dedicated focus on the health of women is at the centre of everything we do, and membership of both MA and GBMA means that we can focus on making a positive contribution toward a healthcare environment which offers patient’s choice, and supports innovation and access in medicines by helping to manage the healthcare budget.”
Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA
This news release of Organon & Co. (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).
Copyright © (2021) Organon group of companies. All rights reserved.
Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. AU-NON-110002. First issued June 2021.